Navigation Links
Genome of Clostridium botulinum reveals the background to world's deadliest toxin

a, and only 16 per cent of the C. botulinum genes are common to all five. Our findings emphasise just how different clostridia are from each other."

C. botulinum toxin stops nerves from working — the basis of its use in medicine to control tremors and in cosmetic treatments. For the prey of its opportunistic attacks, death is swift. Perhaps the most important tool it has to act out its stealth attacks is its ability to hibernate when times are hard by forming dormant spores.

More than 110 of its set of almost 3700 genes are used to control spore formation and germination when opportunity arises.

"C. botulinum shows us one extreme of the ways that bacteria can make the most of animal hosts," explained Dr Julian Parkhill of the Wellcome Trust Sanger Institute. "Some organisms use subtle approaches, elegantly choreographing their interaction with us and our defences.

"C. botulinum takes the opposite approach. It lies in wait and, if it gets the opportunity, it hits its host with a microbial sledgehammer. It then eats the remains and lays low until the next host comes along."

The genome sequence is peppered with genes that produce enzymes to digest proteins and other animal material in the soil. Also found, uniquely in this species, is a range of genes that allow it to attack the many insect and other small creatures that live in the soil. The ‘chitinases’ produced by these genes can degrade the casing of insects and small crustaceans.

It is not only animals that can feel the wrath of C. botulinum, explains Dr Sebaihia: "The soil can be a harsh environment and food can be scarce. To see off the competition, C. botulinum comes with its own ‘antibiotic’ — a chemical called boticin that kills competing bacteria."

Genome sequences can tell us a lot about the biology of the organism, but research into clostridia has been hampered by the lack of a good genetic system. Professor Nigel Minton, Professor
'"/>

Source:University of Nottingham


Page: 1 2 3

Related biology news :

1. Genome of deadly amoeba shows surprising complexity, evidence of lateral gene transfer
2. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
3. Genome-wide mouse study yields link to human leukemia
4. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
5. Multiple Campylobacter Genomes Sequenced
6. Analysis Of Human Genome To Predict The Development Of Illnesses
7. Whole genome promoter mapping - Human Genome Project v2.0?
8. Genome study of beneficial microbe may help boost plant health
9. Candida albicans Genome Fully Annotated
10. Genome Sequence for Haemophilus Influenzae Completed
11. NHGRI Selects 13 More Organisms for Genome Sequencing
Post Your Comments:
(Date:7/11/2014)... 2014 Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... A UC Riverside-led research team has found that as ... they do so by increasing only that segment of ... of an individual to contribute offspring to the next ... have studied for long, the researchers found that guppies ...
... to treat diseases such as cystic fibrosis, reduce bacterial ... and the University of Texas at Austin has determined ... be pivotal in preventing certain bacterial infections in plants, ... the Proceedings of the National Academy of Sciences. ...
... the prevailing belief that adult brain cells don't grow, a ... in the Dec. 27 issue of Public Library of Science ... occur in mature brains. , This finding means that ... to replace ones damaged by disease or spinal cord injury, ...
Cached Biology News:Fish evolve a longer lifespan by evolving a longer reproductive period, researchers find 2Scientists determine structure of enzyme that disrupts bacterial virulence 2MIT researcher finds neuron growth in adult brain 2MIT researcher finds neuron growth in adult brain 3
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... 11 , - TB-402 Shows Clear Promise ... Thromboembolic Disorders., ThromboGenics NV (Euronext Brussels:THR), a ... that the results of the,first Phase I trial ... Society of Hematology (ASH) 49th Annual Meeting in ...
... The Perrigo Company,(Nasdaq: PRGO ; TASE) announced today ... final approval to Dexcel Pharma,Technologies, Ltd. for 20 mg ... this product for the store brand,over-the-counter (OTC) market in ... during the first quarter of calendar year 2008,with full ...
... Tutogen Medical, Inc.,(Amex: TTG ), a leading manufacturer of ... tissue, today announced,financial results for the fiscal year and fourth ... Highlights for the fiscal year include:, -- Total ... of dental products increased 38% in fiscal year 2007; ...
Cached Biology Technology:ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 2Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10
Monocarboxylate (lactate) transporter 2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
... (Ankyrin repeat and SOCS box-containing protein) This ... containing amino acids 75-93 and 348-368 of ... Catalog No. 40149) can be used as ... with mouse and rat Asb-2, based on ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Biology Products: